Eylea Prefilled Syringe Approved
August 13, 2019 – The U.S. FDA has approved a new dosage form of Eylea® (aflibercept) injection prefilled syringe, manufactured by Regeneron Pharmaceuticals. It is indicated to treat patients who have neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), and diabetic retinopathy (DR).
The new prefilled syringe may simplify administration, as physicians do not need to perform as many steps as would be required with the original single-dose vial. Recommended dosing is one 2mg/0.05 mL single-dose prefilled syringe per treatment. The frequency of treatment varies based on the indication. The route of administration, regardless of dosing or dosage form, is intravitreal injection, which must be performed by a qualified healthcare provider. Intravitreal injections deliver a drug directly to the vitreous chamber, a space located behind the lens of the eye that is filled with a gelatinous tissue called the vitreous humor.
Regeneron has not announced pricing plans, but expects to launch the new prefilled syringe before the end of 2019.